Incovacc: nasal vaccine against covid is developed in India and price impresses

Scientists want to create anti-covid spray that acts as a morning-after pill

As studies progress, new formulas and vaccines that protect against covid-19 are starting to hit the market. In the form of a nasal vaccine, the Indian pharmaceutical company Bharat Biotech developed Incovacc. With a very affordable price, of less than 50 reais, the vaccine has already been approved for use in the country of origin.

  • Spray vaccines could revolutionize the fight against covid
  • How is it diagnosed and how long can loss of smell last in long covid?

According to the newspaper The Economic Times, authorization for use by the government of India was granted in November 2022 and is now starting to reach the market. Applied in drops, the nasal vaccine can only be used as a booster dose, in people aged 18 or over.

It is worth remembering that, in September 2022, the first nasal vaccine was approved against covid-19 in the world. The pioneer formula in this type of immunization was developed by the Chinese pharmaceutical company CanSino Biologics and is called Convidecia. In this case, use is also only released as a booster dose.

How much does the nasal vaccine against covid-19 cost?

According to the BBC, the nasal vaccine will cost 800 rupees – approximately 49.7 reais, in direct conversion, without taxes – per dose in private hospitals and 325 rupees – about 20 reais – per dose in public hospitals in India. To be immunized with the booster, it is necessary to receive two doses, 28 days apart.

How does the Incovacc nasal vaccine work?

The Incovacc vaccine uses viral vector technology to induce immunity against the SARS-CoV-2 coronavirus, similarly to Janssen (Johnson & Johnson) and AstraZeneca vaccines — produced by the Oswaldo Cruz Foundation (Fiocruz) in Brazil.

In the case of the Indian formula, an adenovirus is genetically edited and starts to carry part of the genetic code of the covid-19 virus. When entering through the patient’s nostrils, exposure to the vaccine teaches or reminds the patient’s body how to fight that infectious agent.

According to Bharat Biotech, the immunizer successfully completed all stages of clinical trials (Phases I, II and III), focusing on protecting the lining of the nose and upper airways. However, the studies have not been published in a scientific journal to date.

Source: BBC, The Economic Times